Saidal signe un mémorandum d’entente avec le groupe mauritanien « Chinguitty Pharma »
Commercial Agreement between Saidal and Chinguitty Pharma: A Boost for Pharmaceutical Cooperation
On Thursday, the Algerian pharmaceutical group Saidal signed a memorandum of understanding with the Mauritanian company Chinguitty Pharma in Algiers, aimed at enhancing cooperation in various areas, particularly in supplying the Mauritanian market with Algerian pharmaceuticals. The agreement was formalized by interim CEO of Saidal, Soraya Sebbah, and Amar Mohamed Najem, the director general of Chinguitty Pharma, during a ceremony attended by the Minister of Pharmaceutical Industry, Ouacim Kouidri.
Saidal’s Director of Exportation, Othmane Meddad, explained that the initial phase of this collaboration involves Saidal exporting its pharmaceutical products to Chinguitty Pharma, which will manage their commercialization and promotion in the Mauritanian market. Following this, Saidal will provide technical and industrial support for Chinguitty Pharma’s industrial projects, including the establishment of a pharmaceutical solutions production unit and a packaging project in Mauritania. This production facility will allow for the processing of semi-finished products exported by Saidal.
Najem commended this partnership, emphasizing that it resulted from extensive discussions between the two companies and aligns with the broader objectives of both nations to enhance cooperation across multiple sectors. Sidi Mohamed Ould Sidi, a deputy and president of the Mauritanian Health Federation, reiterated the memorandum’s purpose of actualizing the leaders’ commitment to fostering political and economic ties, highlighting the importance of the Tindouf-Zouerate border road in strengthening these relations.
Chinguitty Pharma is a key player in the health sector within Mauritania and West Africa, notable for being the first to secure authorization for establishing a drug manufacturing plant in Mauritania. This collaboration not only signifies a productive relationship between Algeria and Mauritania but also represents a significant stride towards achieving greater integration in the pharmaceutical sector, ultimately contributing to the improvement of healthcare access in the region.
Through this cooperative effort, both companies intend to enhance the local pharmaceutical industry, promote domestic production, and improve the overall availability of medications in Mauritania. By leveraging Saidal’s extensive experience and expertise, the partnership aims to not only meet local healthcare needs but also create new opportunities for growth and development within the Mauritanian pharmaceutical landscape.
This strategic alliance is indicative of a growing trend in the region, where countries are seeking to strengthen bilateral ties through economic collaboration. The emphasis on local production and commercialization of pharmaceuticals aligns with global movements toward reducing reliance on imported medications, enhancing self-sufficiency, and ensuring quicker access to essential medicines.
Looking ahead, the successful implementation of this memorandum could set a precedent for further collaborative efforts between Algerian and Mauritanian health sectors. This partnership is expected to foster innovation, create job opportunities, and develop specific competencies within the pharmaceutical industry in Mauritania, ultimately benefiting the citizens of both nations.
In conclusion, the signing of the memorandum between Saidal and Chinguitty Pharma marks a significant milestone in promoting pharmaceutical cooperation between Algeria and Mauritania. It reflects a commitment to developing the healthcare sector, improving the quality and accessibility of medications, and reinforcing the economic ties between the two countries. As this partnership unfolds, it will be crucial to monitor its impact on local markets and the broader health landscape within the region, paving the way for future collaborations in the pharmaceutical field.
